Cellarity

Cellarity is a private, AI-driven biotech founded in 2017 that is shifting the drug discovery paradigm from single-target to cell-state-focused therapeutics. Its core technology combines high-dimensional single-cell data with AI models to identify novel biological pathways and design oral compounds that correct dysfunctional cellular networks. The company has advanced its first candidate, CLY-124 for sickle cell disease, into clinical development and has established a strategic partnership with Novo Nordisk in metabolic disease, validating its platform's potential.

AI-driven platform integrating single-cell multi-omics data to map disease biology and predict chemical interventions that correct dysfunctional cell states, coupled with a next-generation chemistry engine and lab-in-the-loop validation.

Cellarity competes in the crowded AI/ML drug discovery sector against companies like Recursion, Exscientia, and Insilico Medicine, but differentiates by focusing on cell-state correction rather than single-target optimization. In sickle cell disease, it faces competition from gene therapies (Bluebird Bio, Vertex/CRISPR) and other novel oral therapies, competing on mechanism, safety, and accessibility.